REDWOOD CITY, CA – Seer, Inc. (NASDAQ:SEER), a company specializing in laboratory analytical instruments, announced changes in its executive team and board of directors, according to a recent SEC filing. Elona Kogan, the Chief Legal Officer and Corporate Secretary, will depart from the company effective July 26, 2024, to pursue other career opportunities. Seer has confirmed that Kogan's resignation does not stem from any disagreements with the company's operations, policies, or practices.
In a separate development, Rachel Haurwitz, Ph.D., resigned from the Board of Directors and the Audit Committee on July 12, 2024. Following this, Seer reported to The Nasdaq Stock Market LLC that her departure would leave the company short of meeting Nasdaq's compliance requirements under Listing Rule 5605(c)(2)(A).
To address this issue, on Friday, the board appointed David Hallal, an existing director, to the Audit Committee. Hallal also fulfills the role of the "audit committee financial expert" as defined under Item 407(d)(5)(iii) of Regulation S-K. Seer believes that Hallal's appointment will rectify the potential non-compliance with Nasdaq's Listing Rules.
The changes in Seer's leadership come at a time when the company is navigating through a competitive market in the laboratory analytical instruments sector. The adjustments to the board and executive team are part of the company's efforts to maintain strong governance and oversight.
In other recent news, Seer, Inc. is facing a Nasdaq compliance challenge due to the resignation of Dr. Rachel Haurwitz from its Board of Directors. The company is now working to address this issue by planning to appoint new members to its Audit Committee within the grace period allowed by Nasdaq. In financial developments, Seer reported a 24% decrease in Q1 revenue year-over-year, totaling $3.1 million, primarily due to slower adoption rates of their Proteograph platform. As a strategic response, the company has implemented a 10% workforce reduction and a $25 million share repurchase program, along with the expansion of their commercial team.
Seer also revised its 2024 revenue forecast to be between $16 million and $18 million. In research news, the company announced findings from studies that reveal changes in the human plasma proteome due to spaceflight, led by Dr. Christopher Mason and involving Seer's technology. These studies, published in Nature and Nature Communications, showed significant alterations in proteins related to coagulation, antioxidation, and brain function, which persisted six months after the astronauts returned to Earth. The company's Proteograph technology played a crucial role in these discoveries, and the recent launch of Seer's Proteograph XT Assay Kit promises even more comprehensive proteomics research capabilities. These are recent developments that could potentially impact the future trajectory of the company.
InvestingPro Insights
In light of Seer, Inc.'s recent executive team and board changes, investors may be evaluating the company's financial health and future prospects. According to InvestingPro data, Seer holds a market capitalization of $116.24M, with a Price/Book ratio as of the last twelve months leading to Q1 2024 at 0.3, suggesting the stock might be undervalued relative to its assets. The company's revenue for the same period stands at $15.67M, though it has experienced a revenue decline of 3.45%.
InvestingPro Tips reveal that while Seer holds more cash than debt on its balance sheet, indicating a strong liquidity position, the company is also quickly burning through cash. Analysts have revised their earnings estimates downwards for the upcoming period, and they do not anticipate the company will be profitable this year. Additionally, Seer does not pay a dividend, which may be a consideration for income-focused investors.
For those interested in a deeper analysis, there are additional InvestingPro Tips available that could provide further insights into Seer's financial metrics and performance forecasts. By using the coupon code PRONEWS24, readers can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription to access these valuable resources. It's worth noting that Seer's next earnings date is projected for August 6, 2024, which will be an important event for investors to watch.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.